An analysis of the clinical development of drugs in Norway for the years 2000 and 2004: The influence of the pharmaceutical industry

European Journal of Clinical Pharmacology

Volumn 63, Issue 10, 2007, Pages 909-912

  Winther, Finn O ^a   Hole, Ola P ^a   Nitter Hauge, Sigurd ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; CARDIOVASCULAR AGENT; SEX HORMONE;

ARTICLE; CARDIOVASCULAR SYSTEM; CLINICAL RESEARCH; DERMATOLOGY; DIGESTIVE SYSTEM; DRUG INDUSTRY; HUMAN; IMMUNOMODULATION; MUSCULOSKELETAL SYSTEM; NERVOUS SYSTEM; NORWAY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RESEARCH ETHICS; RESPIRATORY SYSTEM; UROGENITAL SYSTEM;

ACADEMIES AND INSTITUTES; BIAS (EPIDEMIOLOGY); BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DRUG INDUSTRY; HOSPITALS, PRIVATE; HOSPITALS, PUBLIC; HUMANS; NORWAY; RESEARCH SUPPORT AS TOPIC; TIME FACTORS;

EID: 34548561975     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0342-0     Document Type: Article

References (9)

1. Bodenheimer T(2000) Uneasy alliance. Clinical investigators and the pharmaceutical industry. N Engl J Med 342:1539-1544
2. Melander H, Ahlqvist-Rastad J, Mejer G, Beerman B(2003) Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326:1171-1173
3. Lexchin J, Bero LA, Djulbegovic B, Clark O, (2003) Pharmaceutical industry. Sponsorship and research outcome and quality: systematic review. BMJ 326:1167-1170
4. Jorgensen AW, Hilden J, Gotzsche PC (2006) Cochrane reviews compared with industry supported meta-analysis and other meta-analysis of the same drug: systematic review. BMJ 333:782
5. Rang HW, Dale MM, Ritter JM, Moore TK (2003) Pharmacology, 5th ed. Churchill Livingstone, Edinburgh
6. Hole OP, Winther FO, Straume B (2001) Clinical research: the influence of the pharmaceutical industry. Eur J Clin Pharmacol 56:851-853
7. Norwegian Association of Pharmaceutical Manufacturers (2004) Facts and figures. NAMP, Sentrum, Norway, pp 20 and 108
8. Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflict of interests in biomedical research: a systematic review. JAMA 289:454-465
9. Studdert DM, Mello MM, Brennan TA (2004) Financial conflicts of interest in physicians' relationship with the pharmaceutical industry-self regulation in the shadow of federal prosecution. N Engl J Med 351:1891-1900